Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Filgrastim

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    104 result(s) found for: Filgrastim. Displaying page 2 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2004-004545-18 Sponsor Protocol Number: NA Start Date*: 2005-04-26
    Sponsor Name:CHU Sart Tilman
    Full Title: Cell therapy for cardiac repair through mobilization of hematopoietic stem cells and endothelial progenitors in patients with chronic ischemic cardiomyopathy.
    Medical condition: Chronic ischemic cardiac disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003784-68 Sponsor Protocol Number: 4 Start Date*: 2005-04-05
    Sponsor Name:University Hospital Bern
    Full Title: Subcutanoeus Delivery of Filgrastim (rG-CSF) for the Promotion of Collateral Growth in Patients with Coroanry Artery Disease (FILCAD)
    Medical condition: Coronary Artery Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004646-13 Sponsor Protocol Number: 670/05 Start Date*: 2005-11-17
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: PEG-Filgrastim versus Filgrastim as an adjunct to therapy CHOP-14 Rituximab in elderly patients 60-75 years old with B cell non-Hodgkin s High/intermediate grade lymphoma. A randomized, prospe...
    Medical condition: Maintenance of dose-intensity
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025320 HLGT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002136-10 Sponsor Protocol Number: GRIFO-A Start Date*: 2005-07-08
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: Comparison between once-per-cycle peg-Filgrastim and daily injection r-Hu-G-CSF in chemotherapy-induced neutropenia treatment and peripheral blood progenitor cells mobilization in childhood.
    Medical condition: chemotherapy-induced neutropenia treatment peripheral blood progenitor cells mobilization
    Disease: Version SOC Term Classification Code Term Level
    6.1 10029354 PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001741-14 Sponsor Protocol Number: TEM-MM-101 Start Date*: 2018-12-13
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A phase I/II dose escalation study evaluating safety and activity of autologous CD34+-enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human in...
    Medical condition: Multiple myeloma in early relapse after intensive front line therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002228-28 Sponsor Protocol Number: STEMALS-II Start Date*: 2014-09-01
    Sponsor Name:Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
    Full Title: A double blind, placebo controlled, parallel groups, multicenter study on filgrastim in amyotrophic lateral sclerosis
    Medical condition: Amyotrophic lateral sclerosis (ALS) is a severe progressive neurological disorder characterized by a selective degeneration of spinal, bulbar, and cortical motor neurons.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-002429-37 Sponsor Protocol Number: NSGO-EC-9501 Amendment 2 Start Date*: 2004-11-17
    Sponsor Name:Nordic Society for Gynecologic Oncology
    Full Title: A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high-risk endometrial carcinoma NSGO-EC-9501 Amendment 2.
    Medical condition: Endometrial cancer stage I-III radically operated with high-risk factors (high-grade and deep myometrial infiltration, or serous or clear cell histology) that will receive adjuvant treatment with r...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001113-18 Sponsor Protocol Number: GCSFEPO_01 Start Date*: 2006-02-14
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Beeinflussung assoziativen Lernens und motorischer Fähigkeiten durch G-CSF und EPO
    Medical condition: Amyotrophische Lateralsklerose Chronischer Schlaganfall
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014721-16 Sponsor Protocol Number: IRRB/19/09 Start Date*: 2009-11-18
    Sponsor Name:ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE
    Full Title: Controlled randomized pilot study for characterization and identification of CD34+ stem cells in the splancnic distrect after GCSF stimolation in cirrhotic patients
    Medical condition: Liver cirrhosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001152-39 Sponsor Protocol Number: SSG XX Start Date*: 2024-05-21
    Sponsor Name:Scandinavian Sarcoma Group
    Full Title: SSGXX A Scandinavian Sarcoma Group treatment protocol for adult patients with non-metastatic high-risk soft tissue sarcoma of the extremities and trunk wall
    Medical condition: SSG XX is a phase II trial for high-risk soft tissue sarcoma(STS) of the extremities and trunk wall. Prognostic markers are used to identify high-risk tumors. SSG XX will evaluate chemo-and radioth...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003096-20 Sponsor Protocol Number: CDF711 Start Date*: 2005-09-06
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: Use of peg-filgrastim in severe chronic neutropenia
    Medical condition: severe chronic neutropenia
    Disease: Version SOC Term Classification Code Term Level
    6.1 10005329 SOC
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001051-39 Sponsor Protocol Number: FMG-MM-02 Start Date*: 2012-11-15
    Sponsor Name:Kuopio University Hospital, Clinic of Internal Medicine/Center of Medicine
    Full Title: A prospective phase II study to assess immunophenotypic remission after three-drug in-duction followed by randomized stem cell mobilization, autologous stem cell transplantation and lenalidomide ma...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004498-29 Sponsor Protocol Number: 20190360 Start Date*: 2022-01-13
    Sponsor Name:Amgen Inc.
    Full Title: Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor...
    Medical condition: Newly Diagnosed Philadelphia (Ph)-negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024481-22 Sponsor Protocol Number: EP06-302 Start Date*: 2012-01-17
    Sponsor Name:Sandoz GmbH
    Full Title: A randomized, double-blind, parallel-group, multi-center Phase III study comparing the efficacy and safety of EP2006 and Neupogen® in breast cancer patients treated with myelosuppressive chemothe...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006203 Breast cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2018-002697-45 Sponsor Protocol Number: ACT15378 Start Date*: 2019-03-04
    Sponsor Name:Sanofi-aventis recherche & developpement
    Full Title: Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Year...
    Medical condition: Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination with Chemotherapy in Pediatric Patients from 28 Days to Less than 18 Year...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000846 Acute lymphocytic leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed) FI (Completed) DK (Completed) FR (Completed) NL (Completed) PT (Completed) BE (Completed) DE (Completed) CZ (Completed) GR (Completed) Outside EU/EEA IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003544-83 Sponsor Protocol Number: 69HCL19_0375 Start Date*: 2021-03-16
    Sponsor Name:Hospices Civils de Lyon - Direction de la Recherche Clinique
    Full Title: Evaluation de l’efficacité thérapeutique du filgrastim dans les allergies sévères bulleuses aux médicaments s’exprimant sous forme de Lyell et Stevens-Johnson Etude GNET
    Medical condition: Syndrome de Stevens Johnson (SJS) Syndrome de Lyell (NET)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004858 10042030 Stevens Johnson syndrome LLT
    20.0 100000004858 10025166 Lyell syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002545-30 Sponsor Protocol Number: IRAS220495 Start Date*: 2017-11-06
    Sponsor Name:Barts Health NHS Trust
    Full Title: Autologous Stem cell Transplantation In refractory Crohn's disease - Low Intensity Therapy Evaluation
    Medical condition: Refractory Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007161-20 Sponsor Protocol Number: BK0023-02C Start Date*: 2009-01-08
    Sponsor Name:BIO-KER S.R.L
    Full Title: Comparable efficacy and safety profiles of daily injection of BK0023 and filgrastim (Neupogen®) in chemotherapy-induced neutropenia: a multinational, multicenter, investigator blind, randomised, pa...
    Medical condition: Chemotherapy induced Neutropenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029354 Neutropenia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003399-36 Sponsor Protocol Number: MK-4214-008 Start Date*: 2011-10-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized, Double-Blind, Active-Controlled Clinical Trial to Study the Efficacy and Safety of MK-4214 (filgrastim) and Neupogen™ as an Adjunct to Combination Chemotherapy with Doxorubi...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000700-14 Sponsor Protocol Number: R-HDS 0305 Start Date*: 2005-04-12
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE
    Full Title: MULTI-CENTRE, RANDOMISED, PHASE III TRIAL COMPARING HIGH DOSE SEQUENTIAL CHEMOTHERAPY hds WITH RITUXIMAB AND AUTOLOGOUS PERIPHERAL BLOOD PROGENITUR ALL TRANSPLANTION VERSUS 2- WEEKLY CHOP WITH RI...
    Medical condition: ADULT PATIENTS WITH DIFFUSE LARGE B- CELL NON HODGKIN LYMPHOMA
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 04:47:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA